Roche Holding AG banner

Roche Holding AG
OTC:RHHBY

Watchlist Manager
Roche Holding AG Logo
Roche Holding AG
OTC:RHHBY
Watchlist
Price: 51.07 USD 0.51%
Market Cap: $327.1B

P/S

4.2
Current
21%
More Expensive
vs 3-y average of 3.5

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
4.2
=
Market Cap
$279.8B
/
Revenue
CHf61.5B

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
4.2
=
Market Cap
$279.8B
/
Revenue
CHf61.5B

Valuation Scenarios

Roche Holding AG is trading above its 3-year average

If P/S returns to its 3-Year Average (3.5), the stock would be worth $42.07 (18% downside from current price).

Statistics
Positive Scenarios
1/4
Maximum Downside
-53%
Maximum Upside
+7%
Average Downside
19%
Scenario P/S Value Implied Price Upside/Downside
Current Multiple 4.2 $51.07
0%
3-Year Average 3.5 $42.07
-18%
5-Year Average 3.8 $45.56
-11%
Industry Average 4.5 $54.8
+7%
Country Average 2 $23.78
-53%

Forward P/S
Today’s price vs future revenue

Today's Market Cap Revenue Forward P/S
$279.8B
/
Jan 2026
CHf61.5B
=
4.2
Current
$279.8B
/
Dec 2026
CHf63.8B
=
4.4
Forward
$279.8B
/
Dec 2027
CHf66.3B
=
4.2
Forward
$279.8B
/
Dec 2028
CHf69.4B
=
4
Forward

Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
P/S
P/E
All Countries
Close
Market Cap P/S P/E
CH
Roche Holding AG
OTC:RHHBY
248.4B USD 4.2 20.1
US
Eli Lilly and Co
NYSE:LLY
883B USD 14 44.2
US
Johnson & Johnson
NYSE:JNJ
553.5B USD 5.7 26.1
UK
AstraZeneca PLC
LSE:AZN
209.6B GBP 4.7 27.4
CH
Novartis AG
SIX:NOVN
221.1B CHF 5 20.7
US
Merck & Co Inc
NYSE:MRK
270.2B USD 4.3 15.3
IE
Endo International PLC
LSE:0Y5F
244.4B USD 105.4 -83.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.2T DKK 4 12.1
US
Pfizer Inc
NYSE:PFE
151.8B USD 2.4 19.4
US
Bristol-Myers Squibb Co
NYSE:BMY
122B USD 2.4 16.7
FR
Sanofi SA
PAR:SAN
96.5B EUR 1.7 10.2
P/E Multiple
Earnings Growth PEG
CH
Roche Holding AG
OTC:RHHBY
Average P/E: 21.2
20.1
14%
1.4
US
Eli Lilly and Co
NYSE:LLY
44.2
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
26.1
8%
3.3
UK
AstraZeneca PLC
LSE:AZN
27.4
25%
1.1
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
US
Merck & Co Inc
NYSE:MRK
15.3
14%
1.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
12.1
0%
N/A
US
Pfizer Inc
NYSE:PFE
19.4
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.7
16%
1
FR
Sanofi SA
PAR:SAN
10.2
16%
0.6

Market Distribution

Lower than 79% of companies in Switzerland
Percentile
21st
Based on 1 091 companies
21st percentile
0.7
Low
0 — 1
Typical Range
1 — 3.9
High
3.9 —
Distribution Statistics
Switzerland
Min 0
30th Percentile 1
Median 2
70th Percentile 3.9
Max 2 594.8

Roche Holding AG
Glance View

Roche Holding AG, a titan in the world of healthcare, operates from its headquarters in Basel, Switzerland. Established in 1896, Roche has grown into one of the world's leading pharmaceutical and diagnostics companies, driven by a steadfast commitment to advancing medicine and improving lives. Its unique business model is built on two primary pillars: Pharmaceuticals and Diagnostics. The pharmaceutical division focuses on discovering and developing medicines for cancer, immunology, infectious diseases, ophthalmology, and diseases of the central nervous system. A significant portion of its revenue is generated from innovative oncology drugs, which positions Roche as a global leader in cancer treatment. The company's investment in research and development is notably high, emphasizing its dedication to scientific discovery. On the diagnostics front, Roche continually advances its technologies to enhance disease detection and monitoring. This division creates and sells a wide array of diagnostic products and services, ranging from clinical chemistry and immunoassays to molecular biology and tissue diagnostics. By serving hospitals, research labs, and healthcare professionals, Roche Diagnostics aims to make a crucial impact on patient care and health system efficiency. This dual focus on pharmaceuticals and diagnostics allows Roche to capitalize on synergies between drug development and patient diagnostics, often integrating their advancements to provide more tailored and efficient healthcare solutions. The company's financial strength and strategic innovation are underpinned by its ability to adapt to changing market dynamics, ensuring its place as a stalwart in the global healthcare industry.

RHHBY Intrinsic Value
69.47 USD
Undervaluation 26%
Intrinsic Value
Price $51.07
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett